Apparently, the ability of the heparanase inhibitors PG545 and Roneparstat to attenuate cerulein-induced AP appears superior compared with other compounds tested in this experimental model, lending optimism that these heparanase-inhibiting compounds will prove efficacious in the clinic for AP and other heparanase-driven diseases. This evidence concerns the gene HPSE and alkaline phosphatase measurement.